Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-07), Probiotix Health's 3-1 Month Momentum % is 0.73%.
The industry rank for Probiotix Health's 3-1 Month Momentum % or its related term are showing as below:
FRA:X90's 3-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -5.375
vs FRA:X90: 0.73
Probiotix Health (FRA:X90) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Probiotix Health 3-1 Month Momentum % Related Terms
FRA:X90 vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Probiotix Health's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probiotix Health 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Probiotix Health's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Probiotix Health's 3-1 Month Momentum % falls into.
Probiotix Health (FRA:X90) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health (FRA:X90) has a 3-1 Month Momentum % of 0.73% as of Sep. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Probiotix Health and its competitors. According to the industry distribution chart, Probiotix Health ranks #999999 out of 1386 companies in the Biotechnology industry.
Is Probiotix Health's 3-1 Month Momentum % too high?
Probiotix Health's current 3-1 Month Momentum % is 0.73%. Based on the distribution chart, Probiotix Health ranks #999999 out of 1386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Probiotix Health has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Probiotix Health's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #999999 out of 1386 companies for 3-1 Month Momentum %. This places Probiotix Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Probiotix Health and its competitors. Probiotix Health's current 3-1 Month Momentum % is 0.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Probiotix Health (FRA:X90) has a current 3-1 Month Momentum % of 0.73%. The stock's GF Value™ is €0.08, compared to a current price of €0.09 — trading 11.3% above its estimated fair value. The current 3-1 Month Momentum % is 0.73%. Probiotix Health's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Probiotix Health (FRA:X90), the current 3-1 Month Momentum % is 0.73% as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Probiotix Health (FRA:X90) Overvalued in 2026?
Based on GuruFocus' analysis, Probiotix Health stock appears to be overvalued.
The current stock price of €0.09 is trading 11.3% above its estimated GF Value™ of €0.08.
Key valuation signals for FRA:X90:
3-1 Month Momentum %: 0.73%
GF Value™: €0.08 vs. price of €0.09 (11.3% above fair value)
No single metric tells the full story. See the FRA:X90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
32GF Score
Get the complete analysis for FRA:X90
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:X90 has been successfully added to your 
